In line with advice from the Joint Committee on Vaccination and Immunisation, those eligible for a COVID-19 spring vaccine this year include: |
|
Immunosuppressed eligibility age 16 and over* |
Immunosuppressed eligibility aged under 16* |
• Patients undergoing chemotherapy leading to immunosuppression. • Patients undergoing radical radiotherapy. • Solid organ transplant recipients. • Bone marrow or stem cell transplant recipients. • HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID). • Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, • Patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil. • Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults. • Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma. • Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis.
|
• Those undergoing chemotherapy or radiotherapy. • Solid organ transplant recipients. • Bone marrow or stem cell transplant recipients. • Genetic disorders affecting the immune system (e.g. deficiencies of IRAK-4 or NEMO, complement disorder, SCID). • Those with haematological malignancy, including leukaemia and lymphoma. • Those receiving immunosuppressive or immunomodulating biological therapy. • Those treated with or likely to be treated with high or moderate dose corticosteroids. • Those receiving any dose of non-biological oral immune modulating drugs e.g. methotrexate, azathioprine, 6-mercaptopurine or mycophenolate. • Those with auto-immune diseases who may require long term immunosuppressive treatments. • Children who are about to receive planned immunosuppressive therapy should be considered for vaccination prior to commencing therapy. |